IPC Signs MoUs with the Pharmaceuticals & Medical Devices Bureau of India and National Institute of Pharmaceuticals Education & Research, Hajipur, to Promote Drug Quality, Research, and Patient Safety

IPC–PMBI Partnership to Transform Quality Assurance, Strengthen Pharmacovigilance, and Institutionalize Rational Drug Use Across Jan Aushadhi Kendras Nationwide IPC–NIPER Hajipur MoU to Advance Pharmaceutical Research, Strengthen Pharmacopoeial Standards, and Enhance Safety of Biologics and Emerging Therapies Posted On: 24 APR 2026 12:13PM by PIB Delhi Under the visionary leadership of Hon’ble Prime Minister Shri Narendra Modi, India continues to strengthen its commitment to ensuring access to quality healthcare and advancing pharmaceutical excellence through strategic institutional collaborations. In line with this vision, the Indian Pharmacopoeia Commission (IPC), Ministry of Health and Family Welfare, Government of India, signed two significant Memoranda of Understanding (MoUs) with the Pharmaceuticals & Medical Devices Bureau of India (PMBI), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Bihar, an autonomous institution under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. The MoU between IPC and PMBI aims to enhance the quality assurance framework for medicines made available through Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs). Under this collaboration, PMBI may submit randomly selected batches of Jan Aushadhi medicines to IPC for quality testing. The partnership will further promote the use of the National Formulary of India (NFI) across Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) to ensure rational use of medicines. It also seeks to strengthen pharmacovigilance activities by displaying the Pharmacovigilance Programme of India (PvPI) QR code and toll-free helpline number (1800-180-3024) at PMBJKs across the country, thereby encouraging adverse drug reaction (ADR) reporting and improving patient safety. In addition, IPC and PMBI will jointly organize sensitization, awareness, and training programmes for pharmacists and stakeholders on rational use of medicines, pharmacovigilance, ADR reporting tools, and the role of pharmacists in safeguarding public health. The MoU signed between IPC and NIPER, Hajipur focuses on collaborative research, academic exchange, and capacity building in the area of pharmaceutical science and healthcare products. NIPER Hajipur, an Institute of National Importance, possesses advanced expertise in pharmaceutical analysis, biologics, and clinical research, making it a valuable partner in strengthening pharmacopoeial science and patient safety. This collaboration will include joint research programmes on impurity profiling, including genotoxic impurities such as nitrosamines, and their correlation with adverse drug reaction data to establish evidence-based pharmacopoeial limits. It will also focus on the development of analytical methods, quality control protocols, and reference standards for biologics, biosimilars, and emerging cell and gene therapy products for inclusion in the Indian Pharmacopoeia. Both institutions will also collaborate in organizing training programmes, workshops, seminars, and conferences, along with faculty exchange initiatives and sharing of advanced analytical instrumentation facilities. Internship and fellowship opportunities for pharmacy graduates and postgraduates, as well as joint publication of research papers, training manuals, and educational materials, will further strengthen scientific engagement and institutional capacity building. These MoUs reflect IPC’s continued efforts to strengthen India’s healthcare ecosystem by promoting quality assurance, patient safety, rational use of medicines, and innovation in pharmaceutical standards. Such collaborations will further reinforce India’s position as a global leader in pharmaceutical quality, regulatory excellence, and public health advancement. ***** SR HFW/IPC Signs MoUs with PMBI & NIPER to Improve Drug Quality, Research & Patient Safety/24 April 2026/1 (Release ID: 2255190) Visitor Counter : 953 Read this release in: Urdu , हिन्दी , Punjabi Ministry of Health and Family Welfare IPC Signs MoUs with the Pharmaceuticals & Medical Devices Bureau of India and National Institute of Pharmaceuticals Education & Research, Hajipur, to Promote Drug Quality, Research, and Patient Safety IPC–PMBI Partnership to Transform Quality Assurance, Strengthen Pharmacovigilance, and Institutionalize Rational Drug Use Across Jan Aushadhi Kendras Nationwide IPC–NIPER Hajipur MoU to Advance Pharmaceutical Research, Strengthen Pharmacopoeial Standards, and Enhance Safety of Biologics and Emerging Therapies Posted On: 24 APR 2026 12:13PM by PIB Delhi Under the visionary leadership of Hon’ble Prime Minister Shri Narendra Modi, India continues to strengthen its commitment to ensuring access to quality healthcare and advancing pharmaceutical excellence through strategic institutional collaborations. In line with this vision, the Indian Pharmacopoeia Commission (IPC), Ministry of Health and Family Welfare, Government of India, signed two significant Memoranda of Understanding (MoUs) with the Pharmaceuticals & Medical Devices Bureau of India (PMBI), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Bihar, an autonomous institution under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. The MoU between IPC and PMBI aims to enhance the quality assurance framework for medicines made available through Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs). Under this collaboration, PMBI may submit randomly selected batches of Jan Aushadhi medicines to IPC for quality testing. The partnership will further promote the use of the National Formulary of India (NFI) across Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) to ensure rational use of medicines. It also seeks to strengthen pharmacovigilance activities by displaying the Pharmacovigilance Programme of India (PvPI) QR code and toll-free helpline number (1800-180-3024) at PMBJKs across the country, thereby encouraging adverse drug reaction (ADR) reporting and improving patient safety. In addition, IPC and PMBI will jointly organize sensitization, awareness, and training programmes for pharmacists and stakeholders on rational use of medicines, pharmacovigilance, ADR reporting tools, and the role of pharmacists in safeguarding public health. The MoU signed between IPC and NIPER, Hajipur focuses on collaborative research, academic exchange, and capacity building in the area of pharmaceutical science and healthcare products. NIPER Hajipur, an Institute of National Importance, possesses advanced expertise in pharmaceutical analysis, biologics, and clinical research, making it a valuable partner in strengthening pharmacopoeial science and patient safety. This collaboration will include joint research programmes on impurity profiling, including genotoxic impurities such as nitrosamines, and their correlation with adverse drug reaction data to establish evidence-based pharmacopoeial limits. It will also focus on the development of analytical methods, quality control protocols, and reference standards for biologics, biosimilars, and emerging cell and gene therapy products for inclusion in the Indian Pharmacopoeia. Both institutions will also collaborate in organizing training programmes, workshops, seminars, and conferences, along with faculty exchange initiatives and sharing of advanced analytical instrumentation facilities. Internship and fellowship opportunities for pharmacy graduates and postgraduates, as well as joint publication of research papers, training manuals, and educational materials, will further strengthen scientific engagement and institutional capacity building. These MoUs reflect IPC’s continued efforts to strengthen India’s healthcare ecosystem by promoting quality assurance, patient safety, rational use of medicines, and innovation in pharmaceutical standards. Such collaborations will further reinforce India’s position as a global leader in pharmaceutical quality, regulatory excellence, and public health advancement. ***** SR HFW/IPC Signs MoUs with PMBI & NIPER to Improve Drug Quality, Research & Patient Safety/24 April 2026/1 (Release ID: 2255190) IPC–PMBI Partnership to Transform Quality Assurance, Strengthen Pharmacovigilance, and Institutionalize Rational Drug Use Across Jan Aushadhi Kendras Nationwide<br/><br/>IPC–NIPER Hajipur MoU to Advance Pharmaceutical Research, Strengthen Pharmacopoeial Standards, and Enhance Safety of Biologics and Emerging Therapies" /> <span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">Under the visionary leadership of Hon’ble Prime Minister Shri Narendra Modi, India continues to strengthen its commitment to ensuring access to quality healthcare and advancing pharmaceutical excellence through strategic institutional collaborations. In line with this vision, the Indian Pharmacopoeia Commission (IPC), Ministry of Health and Family Welfare, Government of India, signed two significant Memoranda of Understanding (MoUs) with the Pharmaceuticals &amp; Medical Devices Bureau of India (PMBI), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Bihar, an autonomous institution under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India.</span></span></p> <p style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px"><img src="https://static.pib.gov.in/WriteReadData/userfiles/image/image001A160.jpg" style="height:278px; width:602px" /></span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">The MoU between IPC and PMBI aims to enhance the quality assurance framework for medicines made available through Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs). Under this collaboration, PMBI may submit randomly selected batches of Jan Aushadhi medicines to IPC for quality testing. The partnership will further promote the use of the National Formulary of India (NFI) across Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) to ensure rational use of medicines. It also seeks to strengthen pharmacovigilance activities by displaying the Pharmacovigilance Programme of India (PvPI) QR code and toll-free helpline number (1800-180-3024) at PMBJKs across the country, thereby encouraging adverse drug reaction (ADR) reporting and improving patient safety. In addition, IPC and PMBI will jointly organize sensitization, awareness, and training programmes for pharmacists and stakeholders on rational use of medicines, pharmacovigilance, ADR reporting tools, and the role of pharmacists in safeguarding public health.</span></span></p> <p style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px"><img src="https://static.pib.gov.in/WriteReadData/userfiles/image/image002OD2J.jpg" style="height:278px; width:602px" /></span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">The MoU signed between IPC and NIPER, Hajipur focuses on collaborative research, academic exchange, and capacity building in the area of pharmaceutical science and healthcare products. NIPER Hajipur, an Institute of National Importance, possesses advanced expertise in pharmaceutical analysis, biologics, and clinical research, making it a valuable partner in strengthening pharmacopoeial science and patient safety. This collaboration will include joint research programmes on impurity profiling, including genotoxic impurities such as nitrosamines, and their correlation with adverse drug reaction data to establish evidence-based pharmacopoeial limits. It will also focus on the development of analytical methods, quality control protocols, and reference standards for biologics, biosimilars, and emerging cell and gene therapy products for inclusion in the Indian Pharmacopoeia.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">Both institutions will also collaborate in organizing training programmes, workshops, seminars, and conferences, along with faculty exchange initiatives and sharing of advanced analytical instrumentation facilities. Internship and fellowship opportunities for pharmacy graduates and postgraduates, as well as joint publication of research papers, training manuals, and educational materials, will further strengthen scientific engagement and institutional capacity building.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">These MoUs reflect IPC’s continued efforts to strengthen India’s healthcare ecosystem by promoting quality assurance, patient safety, rational use of medicines, and innovation in pharmaceutical standards. Such collaborations will further reinforce India’s position as a global leader in pharmaceutical quality, regulatory excellence, and public health advancement.</span></span></p> <p style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">*****</span></span></p> <p style="text-align:justify"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">SR</span></span></strong></p> <p style="text-align:justify"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">HFW/IPC Signs MoUs with PMBI &amp; NIPER to Improve Drug Quality, Research &amp; Patient Safety/24 April 2026/1</span></span></strong></p> " /> var mPlayer = document.getElementById("background_music"); var mPlayAction = document.getElementById("playbutton"); var isPlaying = false; function playAudio() { mPlayer.play(); isPlaying = true; document.getElementById('stopA').style.display = "block"; document.getElementById('playA').style.display = "none"; } function pauseAudio() { mPlayer.pause(); isPlaying = false; document.getElementById('playA').style.display = "block"; document.getElementById('stopA').style.display = "none"; } //function HandleAudio() { // if (isPlaying == true) { // //Playing already Pause it // pauseAudio(); // } else { // //Play the music // playAudio(); // } //} var synth = window.speechSynthesis; function CleanHtml(html) { html = html.replace(/ /gi, ''); return html; } function stripHtml(html) { let tmp = document.createElement("DIV"); tmp.innerHTML = CleanHtml(html); return tmp.textContent || tmp.innerText || ""; } $(document).ready(function () { //for responsive tables $("table").each(function () { if (!$(this).closest(".table-responsive").length) { $(this).wrap(" "); } }); var width = $(window).width(); if (width $(document).ready(function () { var width = $(window).width(); if (width @media print { .sticky-social, .sticky-social_mb, .pull-right, #printPDF { display: none !important; } } .f_vl { padding-right: 30px; font-size: 17px; cursor: pointer; } .log_oo { // width: 20%; display: flex; justify-content: space-between; } .log_oo img { width: 150px; /*width: 100%; height: auto;*/ } .sticky-social_mb { position: fixed; bottom: 0px; padding: 0px; margin: 0px; width: 100%; } .social_mb { list-style: none; display: flex; width: 100%; margin-bottom: -8px; } .social_mb a { padding: 8px 0px; font-size: 30px; transition: all 0.8s ease-in-out; width: 20% !important; text-align: center; } .section1 { position: relative; padding: 10px 0px; width: 100%; } .sticky-social { position: fixed; top: 20px; left: 0px; padding: 0px; margin: 0px; } .social { list-style: none; } .social a li { padding: 8px 12px; font-size: 25px; transition: all 0.8s ease-in-out; } .social a li:hover { margin-right: -30px; box-shadow: 2px 5px 10px grey; } .social a li:hover .fa { margin-left: 20px; } .fb_b { /* background-color: rgb(59, 89, 152);*/ background-color: rgba(65,103,178,255); } .twitter_r { /* background-color: rgb(29, 161, 242);*/ background-color: #000000; } .whatsapp_r { /* background-color: rgb(77, 194, 71);*/ background-color: rgba(13,191,67,255); } .fa-envelope_r { /* background-color: rgb(219, 68, 55);*/ background-color: #e2123d; } .fa-linkedin_r { background-color: rgb(0, 119, 181); } @media only screen and (max-device-width: 767px) { p span img { max-width: 90% !important; height: auto !important; } p img { max-width: 90% !important; height: auto !important; } h2 { font-size: 20px !important; font-weight: 600 !important; } h3 { font-size: 18px !important; font-weight: 600 !important; } } /* === Film Roll Badge Styling(IFFI2025 countdown) === */ .film-roll-badge { position: absolute; top:82%; right: 20px; width: 230px; height: 70px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 18px, #6e2b8b 18px, #6e2b8b 36px ); border-top: 8px solid #9a2375; border-bottom: 8px solid #9a2375; border-radius: 8px; overflow: hidden; box-shadow: 0 4px 12px rgba(0, 0, 0, 0.4); animation: moveFilm 8s linear infinite; z-index: 10; } /* film sprocket holes */ .film-roll-badge::before, .film-roll-badge::after { content: ""; position: absolute; width: 100%; height: 10px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 10px, #fff 10px, #fff 20px ); left: 0; z-index: 2; } .film-roll-badge::before { top: -4px; } .film-roll-badge::after { bottom: -4px; } .film-roll-inner { position: relative; height: 100%; display: flex; align-items: center; justify-content: center; animation: flicker 2s infinite ease-in-out; } .countdown-text { font-size: 1.3rem; font-weight: 700; color: #fff; text-shadow: 0 0 6px rgba(255, 255, 255, 0.4), 0 0 10px #000; white-space: nowrap; } /* === Animations === */ @keyframes moveFilm { 0% { background-position: 0 0; } 100% { background-position: 120px 0; } } @keyframes flicker { 0%, 100% { opacity: 1; } 50% { opacity: 0.9; } 25% { opacity: 0.95; } 75% { opacity: 0.85; } } /* === Responsive Adjustments === */ @media (max-width: 1500px) { .film-roll-badge { top: 68%; right: 18px; /* width: 220px; */ height: 65px; font-size: 0.85rem; } .press-section { margin-top: 35px; } } @media (max-width: 992px) { .film-roll-badge { top: 52%; right: 10px; width: 200px; height: 60px; } } @media (max-width: 768px) { .film-roll-badge { top: 56%; right: 10px; width: 124px; height: 55px; } .countdown-text { font-size: 0.9rem; } } @media (max-width: 576px) { .film-roll-badge { top: 59%; right: 5px; /* width: 160px; */ height: 50px; } .countdown-text { font-size: 0.85rem; } } const festivalStart = new Date("2025-11-20T00:00:00").getTime(); const festivalEnd = new Date("2025-11-28T23:59:59").getTime(); const countdownElement = document.getElementById("countdown"); const interval = setInterval(() => { const now = new Date().getTime(); // BEFORE FESTIVAL — show days + hours left if (now = festivalStart && now el.style.width = "350px"); clearInterval(interval); } }, 1000); //